Systematic review: Asian patients with chronic hepatitis C infection

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.12300PMID 23557103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High Proportion of Hepatitis C Virus in Community Asian American Patients With Non–Liver-related Complaints

  2013cited by this paper
• The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings

  2012cited by this paper
• 460 Ethnic Differences in Clinical Characteristics and Treatments of Asian and Non-Asian With Hepatitis C (HCV)-Related Hepatocellular Carcinoma (HCC)

  2012cited by this paper
• A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

  2012cited by this paper
• Role of interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

  2011cited by this paper
• Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C.

  2011cited by this paper
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cited by this paper
• The effects of widespread methadone treatment on the molecular epidemiology of hepatitis C virus infection among injection drug users in Hong Kong

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• A comparison of the natural history and outcome of treatment for Asian and non‐Asian hepatitis C‐infected patients

  2011cited by this paper
• Association of a single nucleotide polymorphism near the interleukin‐28B gene with response to hepatitis C therapy in Asian patients

  2011cited by this paper
• Vietnamese community screening for hepatitis B virus and hepatitis C virus

  2011cited by this paper
• Sustained HCV Clearance by Interferon-Based Therapy Reduces Hepatocellular Carcinoma in Hepatitis B and C Dually-Infected Patients

  2011cited by this paper
• Hepatitis C virus genotypes in Pakistan: a systemic review

  2011cited by this paper
• Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial

  2011cited by this paper
• New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors

  2011cited by this paper
• Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

  2011cited by this paper
• Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection

  2011cited by this paper
• High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic.

  2011cited by this paper
• A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

  2011cited by this paper
• IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies

  2011cited by this paper
• The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B

  2011cited by this paper
• Seroprevalence and Genotype of Hepatitis C Virus among Immigrant Workers from Cambodia and Myanmar in Thailand

  2010cited by this paper
• Epidemiology of hepatitis B and C viruses: a global overview.

  2010cited by this paper
• Prevalence and Incidence of HCV Infection among Vietnam Heroin Users with Recent Onset of Injection

  2010cited by this paper
• High Prevalence and Genetic Diversity of HCV among HIV-1 Infected People from Various High-Risk Groups in China

  2010cited by this paper
• Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6

  2010cited by this paper
• Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

  2010cited by this paper
• The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos

  2010cited by this paper
• The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report

  2010cited by this paper
• Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans

  2010cited by this paper
• Outcome of sustained virological responders with histologically advanced chronic hepatitis C

  2010cited by this paper
• Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans

  2010cited by this paper
• A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.

  2010cited by this paper
• Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1

  2010cited by this paper
• IL28B and the control of hepatitis C virus infection.

  2010cited by this paper
• Randomized controlled trial of pegylated interferon‐alfa 2a and ribavirin in treatment‐naive chronic hepatitis C genotype 6

  2010cited by this paper
• Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis

  2010cited by this paper
• Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis C

  2010cited by this paper
• A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.

  2010cited by this paper
• Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening.

  2010cited by this paper
• Prevalence and factors associated with hepatitis C virus infection among Myanmar blood donors.

  2010cited by this paper
• Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.

  2010cited by this paper
• Hepatitis C in Pakistan: A Review of Available Data

  2010cited by this paper
• Anti-HCV reactive volunteer blood donors distribution character and genotypes switch in Xi'an, China

  2010cited by this paper
• Prevalence of hepatitis B virus genotype B in Vietnamese patients with chronic hepatitis B

  2009cited by this paper
• Changes in modes of hepatitis C infection acquisition and genotypes in southwest China.

  2009cited by this paper
• Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

  2009cited by this paper
• Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort.

  2009cited by this paper
• Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  2009cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Prevalence of hepatitis B and hepatitis C virus infections in potential blood donors in rural Cambodia.

  2009cited by this paper
• Hepatitis C seroprevalence and associated risk factors, Anyang, China.

  2009cited by this paper
• High prevalence of Hepatitis C virus genotype 6 in Vietnam.

  2009cited by this paper
• Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

  2009cited by this paper
• 10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS

  2009cited by this paper
• Genotype diversity of hepatitis C virus (HCV) in HCV‐associated liver disease patients in Indonesia

  2009cited by this paper
• The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patients

  2009cited by this paper
• Interferon‐induced thyroid dysfunction in chronic hepatitis C

  2009cited by this paper
• Tracking the entry routes of hepatitis C virus as a surrogate of HIV in an HIV‐low prevalence country, the Philippines

  2009cited by this paper
• Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• Hepatitis C Virus Genotype in Blood Donors and Associated Liver Disease in Indonesia

  2009cited by this paper
• Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors.

  2009cited by this paper
• TRANSFUSION COMPLICATIONS: Declining hepatitis C virus (HCV) prevalence in pregnant women: impact of anti‐HCV screening of donated blood

  2009cited by this paper
• Treatment responses in Asians and Caucasians with chronic hepatitis C infection.

  2008cited by this paper
• Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India.

  2008cited by this paper
• HCV infection in voluntary donors and its influence on recruitment of donors in Chongqing area.

  2008cited by this paper
• Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5

  2008cited by this paper
• The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.

  2008cited by this paper
• Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0

  2008cited by this paper
• Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

  2008cited by this paper
• Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight‐based ribavirin exposure

  2008cited by this paper
• Higher Rate of Sustained Virologic Response in Chronic Hepatitis C Genotype 6 Treated With 48 Weeks Versus 24 Weeks of Peginterferon Plus Ribavirin

  2008cited by this paper
• Virological Pattern in Plasma, Peripheral Blood Mononuclear Cells and Liver Tissue and Clinical Outcome in Chronic Hepatitis B and C virus Coinfection

  2008cited by this paper
• Genetic History of Hepatitis C Virus in East Asia

  2008cited by this paper
• [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].

  2008cited by this paper
• The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India.

  2008cited by this paper
• Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.

  2007cited by this paper
• Prevalence and risk factors for hepatitis C infection in rural north Vietnam

  2007cited by this paper
• Genotyping of Hepatitis C virus (HCV) in infected patients from South India.

  2007cited by this paper
• Seroprevalence of hepatitis B and C virus infections among Lao blood donors.

  2007cited by this paper
• Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype

  2007cited by this paper
• The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants.

  2007cited by this paper
• Seroepidemiology and genotypes of hepatitis C virus in Thailand.

  2007cited by this paper
• Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C

  2007cited by this paper
• Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants.

  2007cited by this paper
• Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis

  2007cited by this paper
• Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin

  2007cited by this paper
• Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV‐endemic areas in an HBV‐endemic country: Geographic variations among 502 villages in southern Taiwan

  2007cited by this paper
• Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay

  2007cited by this paper
• Inferior response of Asian vs non‐Asian hepatitis C genotype 3 infection to combination antiviral therapy

  2007cited by this paper
• Report of the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan †

  2007cited by this paper
• Peginterferon α‐2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients

  2007cited by this paper
• Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study

  2006cited by this paper
• Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications.

  2006cited by this paper
• Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong

  2006cited by this paper

• Comparative prognostic performance of staging systems for hepatocellular carcinoma: Evidence from a Vietnamese cohort study

  2025cites this paper
• Epidemiology, treatment and diagnosis of Hepatitis C virus infections.

  2025cites this paper
• Evaluation of Hepatitis C Viral Load Between a Sample of Acute and Chronic Patients in Relation with Some Biovital and Biochemical Markers

  2025cites this paper
• Liver Cancer Etiology in Asian Subgroups and American Indian, Black, Latino, and White Populations

  2025cites this paper
• Serum Lactadherin as a Diagnostic Biomarker in Hepatitis C Virus Cirrhotic Patients with and without Hepatocellular Carcinoma

  2024cites this paper
• Socio-demographic association with confirmed hepatitis C virus infection: A cross-sectional analysis from a teaching institute

  2024cites this paper
• An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats

  2023cites this paper
• C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study

  2022cites this paper
• Sociodemographic characteristics associated with hepatitis C virus infection in Vietnamese Americans: A cross-sectional analysis of community screening data

  2022cites this paper
• Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1–Induced OCT4/Nanog Pathway

  2022cites this paper
• Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis

  2021cites this paper
• Sorafenib use in hepatitis B virus‐ or hepatitis C virus‐related hepatocellular carcinoma: A propensity score matching study

  2021cites this paper
• High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis among Mongols in Southern California

  2020cites this paper
• Twelve weeks of ledipasvir/sofosbuvir all‐oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials

  2020cites this paper
• Prevalence and Characteristics of Chronic Hepatitis C Among Asian Americans Are Distinct From Other Ethnic Groups

  2020cites this paper
• Prospective Study

  2020cites this paper
• Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)

  2020cites this paper
• A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin

  2019cites this paper
• South Asian Health: Inflammation, Infection, Exposure, and the Human Microbiome

  2019cites this paper
• Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis

  2019cites this paper
• International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting—From Noncirrhotic to Decompensated Disease and After Liver Transplantation

  2019cites this paper
• Disparities in Hepatocellular Carcinoma Incidence in California: An Update

  2019cites this paper
• Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening

  2019influential citation
• Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.

  2019cites this paper
• Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

  2019cites this paper
• Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas

  2019influential citation
• Novel Polymorphism in the Promoter Region of HLA-DQB1 Is a Predictor of Anti-HCV Therapy Response

  2019cites this paper
• Epidemiology of Viral Hepatitis B, C, and D: A Global View

  2019cites this paper
• MicroRNA‐191 promotes hepatocellular carcinoma cell proliferation by has_circ_0000204/miR‐191/KLF6 axis

  2019cites this paper
• Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.

  2019cites this paper
• Humanized Mouse Models for the Study of Hepatitis C and Host Interactions

  2019cites this paper
• Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6

  2019cites this paper
• Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

  2019cites this paper
• Prevalence of Chronic Hepatitis B and C Infection in Mongolian Immigrants in the Washington, District of Columbia, Metropolitan Area, 2016–2017

  2019cites this paper
• Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir

  2018cites this paper
• Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

  2018cites this paper
• Cancer Risk, Risk Reduction, and Screening and Treatment Access among U.S. South Asians

  2018cites this paper
• The Role Of ARFI And APRI In Diagnosis Of Liver Fibrosis On Patients With Common Chronic Liver Diseases

  2018cites this paper
• The changing epidemiology of liver diseases in the Asia–Pacific region

  2018cites this paper
• Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

  2018cites this paper
• Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia

  2018cites this paper
• The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review

  2018cites this paper
• Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations

  2018cites this paper
• Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis

  2018cites this paper
• Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon

  2018cites this paper
• Clinical characteristics of patients with chronic hepatitis c infection at initial presentation to tertiary care in an Asian middle-income country Azzeri,

  2018cites this paper
• Large Disparity between Prevalence and Treatment Rates for Hepatitis C in Western China

  2018cites this paper
• Surveillance des hépatites virales B-C au Laos : de l'analyse de routine à la recherche de biomarqueurs par métabolomique

  2018cites this paper
• Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada.

  2018cites this paper
• Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents

  2018cites this paper
• Hepatitis C in Developing Countries in Southeast Asia

  2018cites this paper
• Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience

  2017cites this paper
• Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response

  2017cites this paper
• Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

  2017cites this paper
• HCV Prevalence in Asian Americans in California

  2017cites this paper
• Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data

  2017cites this paper
• Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients

  2017cites this paper
• Disparities in liver cancer occurrence in the United States by race/ethnicity and state

  2017cites this paper
• Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease

  2017influential citation
• Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti‐viral therapy with an interferon‐free regimen

  2017cites this paper
• HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis

  2017cites this paper
• Types and microbiological spectrum of infections in patients with cirrhosis: A single-centre experience in Upper Egypt.

  2017cites this paper
• Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection

  2017cites this paper
• Urgency to treat patients with chronic hepatitis C in Asia

  2017cites this paper
• The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.

  2017cites this paper
• Clinical Characteristics Of Patients With Chronic Hepatitis C Infection At Initial Presentation To Tertiary Care In An Asian Middle-Income Country

  2017cites this paper
• Viral Hepatitis: Hepatitis C

  2017cites this paper
• Is Tattooing a Risk Factor for Hepatitis C Transmission?: An Updated Systematic Review and Meta-Analysis

  2017cites this paper
• Review Reviews of Research on Risk Factors of Hepatitis C Virus Infection

  2017cites this paper
• Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.

  2016cites this paper
• Cost‐effectiveness of strategy‐based approach to treatment of genotype 1 chronic hepatitis C

  2016cites this paper
• Hepatitis C Genotype Prevalence in Monastir Region, Tunisia: Correlation between 5′ Untranslated Region (5′UTR), Non-structural 5B (NS5B), and Core Sequences in HCV Subtyping

  2016cites this paper
• MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1α feedback loop.

  2016cites this paper
• Adverse events associated with ribavirin in sofosbuvir‐based therapies for patients with chronic hepatitis C: A community practice experience

  2016cites this paper
• Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection

  2016influential citation
• How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study

  2016cites this paper
• Toward a simple risk assessment screening tool for HCV infection in Egypt

  2016cites this paper
• More clinical guideline inconsistency regarding the prevention of hepatitis B and C virus transmission.

  2016cites this paper
• Interferon lambda polymorphisms: validation and characterisation

  2016cites this paper
• Forty Years Fast Forward: Vietnamese Refugees in the United States with Comments on Their Cancer Care

  2016cites this paper
• Liver Cancer Among Asian Americans

  2016cites this paper
• [EPIDEMIOLOGIC MANIFESTATIONS OF VIRAL HEPATITIS C IN REPRESENTATIVES OF CAUCASIAN AND MONGOLOID RACES].

  2016cites this paper
• Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection

  2016cites this paper
• Racial Disparities in Treatment Rates for Chronic Hepatitis C

  2016cites this paper
• Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia

  2016cites this paper
• Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis

  2015cites this paper
• MiR-21 and miR-183 can simultaneously target SOCS6 and modulate growth and invasion of hepatocellular carcinoma (HCC) cells.

  2015cites this paper
• Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C

  2015cites this paper
• A comprehensive hepatitis C virus risk factors meta‐analysis (1989–2013); Do they differ in Egypt?

  2015cites this paper
• Assessment for Risk of Bias in Systematic Reviews and Meta-Analyses in the Field of Hepatology

  2015cites this paper
• Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.

  2015cites this paper
• Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care

  2015cites this paper
• Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population.

  2015influential citation
• Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis

  2015cites this paper
• Viral Hepatitis Among Non-Hispanic Asian Adults in the United States, 2011-2014.

  2015cites this paper
• Reviews of Research on Risk Factors of Hepatitis C Virus Infection

  2015cites this paper
• Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1

  2015cites this paper
• HCV Screening Behaviors and Infection Status among Vietnamese Americans.

  2015cites this paper
• MiR-21 and miR-183 can simultaneously target SOCS6 and modulate growth and invasion of hepatocellular carcinoma (HCC) cells

  2015cites this paper
• The 3D-QSAR and pharmacophore studies of pyrimidine derivatives as HCV replication (replicase) inhibitor

  2015influential citation